Investor Presentation Q1-Q3 2020

24 Investor presentation First nine months of 2020 Sales growth of 7% at CER, mainly driven by the Diabetes and Obesity care segment Novo Nordisk reported quarterly sales DKK billion by therapy Reported sales for the first nine months of 2020 40 331250 Reported sales CAGR1: 6.7% Other Biopharm Growth disorders 1% Haemophilia 6% (4.3%)¹ 8% 4.3%1 Obesity 4% 1.5%1 7.9%1 Novo NordiskⓇ Reported sales and growth breakdown for the first nine months of 2020 Therapy Sales (mDKK) Growth Share of growth Long-acting insulin² 13,426 (13%) (33%) Premix insulin³ 8,220 6% 8% Fast-acting insulin 14,082 (1%) (2%) Human insulin 7,195 8% 9% Total insulin 42,923 (3%) (18%) GLP-15 30,051 29% 107% Other Diabetes care6 3,056 (4%) (2%) Total Diabetes care 76,030 8% 87% Obesity care (SaxendaⓇ) 4,223 6% 4% Diabetes and Obesity care 80,253 8% 91% 80% Haemophilia7 7,522 (2%) (2%) Diabetes care Growth disorders 5,872 13% 11% (NorditropinⓇ) Other Biopharm³ Biopharm 1,161 1% 0% 14,555 3% 9% Total 94,808 7% 100% 5 0 Q3 Other 2010 NorditropinⓇ Q3 2020 ■Haemophilia Diabetes and Obesity care Sales of DKK 94.8 billion (+7%) 1 CAGR for 10-year period; 2 Comprises Tresiba®, XultophyⓇ and LevemirⓇ; 3 Comprises RyzodegⓇ and NovoMix®: 4 Comprises FiaspⓇ and NovoRapid: 5 Comprises Victoza®, Ozempic®, Rybelsus®; 6 Primarily NovonormⓇ, needles and GlucaGen® HypoKitⓇ; 7 Comprises Novo Seven®, Novo Eight®, NovoThirteen® Refixia®, and EsperoctⓇ8 Primarily Vagifem®, Activelle®, Macrilen® Note: Refixia® and NovoThirteenⓇ are launched as RebinynⓇ and TRETTENⓇ, respectively, in North America. Note: Sales numbers are reported in Danish kroner; Growth is at constant exchange rates

View entire presentation